ValuEngine upgraded shares of Krystal Biotech (NASDAQ:KRYS) from a hold rating to a buy rating in a research note published on Friday, September 21st.
A number of other equities research analysts have also recently issued reports on KRYS. LADENBURG THALM/SH SH set a $38.00 target price on shares of Krystal Biotech and gave the company a buy rating in a report on Thursday, July 19th. Chardan Capital assumed coverage on shares of Krystal Biotech in a research note on Thursday, June 28th. They issued a buy rating and a $35.00 price target on the stock. Zacks Investment Research upgraded shares of Krystal Biotech from a hold rating to a buy rating and set a $18.00 price target on the stock in a research note on Saturday, August 11th. William Blair initiated coverage on shares of Krystal Biotech in a research note on Tuesday, July 10th. They issued an outperform rating on the stock. Finally, Cantor Fitzgerald initiated coverage on shares of Krystal Biotech in a research report on Monday, September 10th. They set an overweight rating and a $28.00 target price on the stock. Seven investment analysts have rated the stock with a buy rating, The stock has an average rating of Buy and a consensus target price of $30.20.
KRYS traded up $0.64 during trading on Friday, hitting $16.14. The company had a trading volume of 2,616 shares, compared to its average volume of 32,254. Krystal Biotech has a one year low of $8.03 and a one year high of $21.17. The stock has a market capitalization of $182.02 million and a P/E ratio of -10.91.
A hedge fund recently raised its stake in Krystal Biotech stock. Acadian Asset Management LLC boosted its stake in Krystal Biotech Inc (NASDAQ:KRYS) by 552.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 12,202 shares of the company’s stock after purchasing an additional 10,331 shares during the period. Acadian Asset Management LLC owned about 0.12% of Krystal Biotech worth $182,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 23.07% of the company’s stock.
About Krystal Biotech
Krystal Biotech, Inc, a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in preclinical development to treat dystrophic epidermolysis bullosa, a genetic disease.
See Also: Why does a company issue an IPO?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.